BCRX Q3 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$117M+35.0% YoY

Gross Profit

$114M97.2% margin

Operating Income

$8M6.6% margin

Net Income

-$14M-12.0% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+7.1%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

$8M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$491M

Total Liabilities

$960M

Stockholders' Equity

-$469M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$117M	$87M	+35.0%
Gross Profit	$114M	$86M	+33.0%
Operating Income	$8M	-$12M	+164.5%
Net Income	-$14M	-$36M	+61.2%

Revenue Segments

Product

$116M99%

Collaborative and Other Research and Development

$1M1%